These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

440 related articles for article (PubMed ID: 24690241)

  • 1. GPCR-targeting nanobodies: attractive research tools, diagnostics, and therapeutics.
    Mujić-Delić A; de Wit RH; Verkaar F; Smit MJ
    Trends Pharmacol Sci; 2014 May; 35(5):247-55. PubMed ID: 24690241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanobodies: New avenues for imaging, stabilizing and modulating GPCRs.
    De Groof TWM; Bobkov V; Heukers R; Smit MJ
    Mol Cell Endocrinol; 2019 Mar; 484():15-24. PubMed ID: 30690070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanobodies detecting and modulating GPCRs outside in and inside out.
    Heukers R; De Groof TWM; Smit MJ
    Curr Opin Cell Biol; 2019 Apr; 57():115-122. PubMed ID: 30849632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanobodies and their Use in GPCR Drug Discovery.
    Cromie KD; Van Heeke G; Boutton C
    Curr Top Med Chem; 2015; 15(24):2543-57. PubMed ID: 26126902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation and characterization of nanobodies targeting GPCR.
    Zhang S; Fan Z; Liu J
    Biophys Rep; 2024 Feb; 10(1):22-30. PubMed ID: 38737476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibodies Targeting Chemokine Receptors CXCR4 and ACKR3.
    Bobkov V; Arimont M; Zarca A; De Groof TWM; van der Woning B; de Haard H; Smit MJ
    Mol Pharmacol; 2019 Dec; 96(6):753-764. PubMed ID: 31481460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Impact of Nanobodies on G Protein-Coupled Receptor Structural Biology and Their Potential as Therapeutic Agents.
    Salom D; Wu A; Liu CC; Palczewski K
    Mol Pharmacol; 2024 Sep; 106(4):155-163. PubMed ID: 39107078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanobodies as Probes and Modulators of Cardiovascular G Protein-Coupled Receptors.
    Wingler LM; Feld AP
    J Cardiovasc Pharmacol; 2022 Sep; 80(3):342-353. PubMed ID: 34840268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibodies targeting G protein-coupled receptors: Recent advances and therapeutic challenges.
    Ayoub MA; Crépieux P; Koglin M; Parmentier M; Pin JP; Poupon A; Reiter E; Smit M; Steyaert J; Watier H; Wilkinson T
    MAbs; 2017 Jul; 9(5):735-741. PubMed ID: 28475474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Yeast surface display platform for rapid discovery of conformationally selective nanobodies.
    McMahon C; Baier AS; Pascolutti R; Wegrecki M; Zheng S; Ong JX; Erlandson SC; Hilger D; Rasmussen SGF; Ring AM; Manglik A; Kruse AC
    Nat Struct Mol Biol; 2018 Mar; 25(3):289-296. PubMed ID: 29434346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural basis for selectivity and antagonism in extracellular GPCR-nanobodies.
    Schlimgen RR; Peterson FC; Heukers R; Smit MJ; McCorvy JD; Volkman BF
    Nat Commun; 2024 May; 15(1):4611. PubMed ID: 38816420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Introduction to heavy chain antibodies and derived Nanobodies.
    Vincke C; Muyldermans S
    Methods Mol Biol; 2012; 911():15-26. PubMed ID: 22886243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cryo-EM advances in GPCR structure determination.
    Shihoya W; Iwama A; Sano FK; Nureki O
    J Biochem; 2024 Jul; 176(1):1-10. PubMed ID: 38498911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High yield purification of nanobodies from the periplasm of E. coli as fusions with the maltose binding protein.
    Salema V; Fernández LÁ
    Protein Expr Purif; 2013 Sep; 91(1):42-8. PubMed ID: 23856605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of Useful Nanobodies by Phage Display of Immune Single Domain Libraries Derived from Camelid Heavy Chain Antibodies.
    Romao E; Morales-Yanez F; Hu Y; Crauwels M; De Pauw P; Hassanzadeh GG; Devoogdt N; Ackaert C; Vincke C; Muyldermans S
    Curr Pharm Des; 2016; 22(43):6500-6518. PubMed ID: 27669966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanobody-based products as research and diagnostic tools.
    De Meyer T; Muyldermans S; Depicker A
    Trends Biotechnol; 2014 May; 32(5):263-70. PubMed ID: 24698358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanobodies: natural single-domain antibodies.
    Muyldermans S
    Annu Rev Biochem; 2013; 82():775-97. PubMed ID: 23495938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanobodies®: proficient tools in diagnostics.
    Huang L; Muyldermans S; Saerens D
    Expert Rev Mol Diagn; 2010 Sep; 10(6):777-85. PubMed ID: 20843201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanobodies: From Serendipitous Discovery of Heavy Chain-Only Antibodies in Camelids to a Wide Range of Useful Applications.
    Ji F; Ren J; Vincke C; Jia L; Muyldermans S
    Methods Mol Biol; 2022; 2446():3-17. PubMed ID: 35157266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanobodies and their potential applications.
    Hassanzadeh-Ghassabeh G; Devoogdt N; De Pauw P; Vincke C; Muyldermans S
    Nanomedicine (Lond); 2013 Jun; 8(6):1013-26. PubMed ID: 23730699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.